

Ref No: SPL/Corp.Sec/2021-22/74

Dated:14-08-2021

To, Department of Corporate Services Bombay Stock Exchange Limited, Phirojshah Jeejobhoy tower, Dalal Street, Mumbai-400001.

Sub:Nil Statement on Deviation or Variation in utilization of Funds raised through Preferential Issue

Pursuant to the provisions of Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular no CIR/CFD/CMD1/162/2019 Dated December 24, 2019 regarding "Format on Statement of Deviation or Variation for proceeds of Public issue, right issue, preferential issue, Qualified Institutions Placement (QIP) etc Please find enclosed herewith A Nil statement of deviation, duly reviewed by the Audit Committee of the Company , is given in "Annexure -A" for the 01^{st} Tranche.

You are requested to kindly take note of the same.

Thanking you, Yours Faithfully, **FOR SANDU PHARMACEUTICALS LTD.**

ACEII anbious

Pratika Mhambray Company Secretary



Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071. Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in CIN:L24233GA1985PLC001587





SANDU PHARMACEUTICALS LTD

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071. Tel : +91 22 25284402/3306, Fax : +91 22 25282403, E-mail : info@sandu.in, Web : www.sandu.in

Statement of Deviation/Variation in utilization of funds raised

Name of Listed Entity	Sandu Pharmaceuticals Limited					
Mode of Fund Raising	Preferential issue of Equity Warrants to be converted into Equity Shares					
Date of Raising Funds	31-03-2021(25% upfront amount of the Share Warrants)					
Amount Raised	2,63,79,653					
Report filed for Quarter ended	30 th June 2021					
Monitoring Agency	NA					
Monitoring Agency name if applicable	NA					
ls there a Deviation/Variation in use of funds raised	NO					
If yes, whether the same is pursuant to change in terms contract or objects, which was approved by the shareholders						
lf yes, date of Shareholders Approval	Not Applicable					
Explanation for the Deviation/Variation	Not Applicable					
Comments of the	No Comments					







SANDU PHARMACEUTICALS LTD

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071. Tel : +91 22 25284402/3306, Fax : +91 22 25282403, E-mail : info@sandu.in, Web : www.sandu.in

Audit Committee after review								
Comments of the Auditors, if any	No Comments							
Objects for which funds have been raised and where there has been a deviation, in the following table								
Original object	Modified Objects, if any	Original Allocation	Modified Allocatio n, if any	Funds Utilise d	Amount of Deviation/Variatio n for the quarter according to applicable object	Remark s if any		
The Company shall use the proceeds from the proposed issue towards the revamping of the existing capital machinery, developing marketing infrastructure, civil work, required for major plant and machinery, purchase of new/ additional plant and machinery of the company, working capital requirement,	e	2,63,79,653	Not applicabl e	0	NIL	NIL		







SANDU PHARMACEUTICALS LTD

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071. Tel : +91 22 25284402/3306, Fax : +91 22 25282403, E-mail : info@sandu.in, Web : www.sandu.in

investment in			
technologies and			
for general purpose			
which shall enhance			
the business of the			
Company			
Mada	1	1	 I


Note:

1. The Company has allotted 25,79,990 nos of Equity Warrants to be Converted into Equity Shares at the face value of Rs. 10/- Each and at the premium of Rs 10.69 each carrying a right exercisable by the warrant holder to subscribe to one Equity Share per Warrant within 18 months from allotment to Promoters and Non Promoters of the Company.

2. The 01st Tranche of Equity Warrants conversion into Equity shares was done on 31st March 2021 wherein 8,39,997 Equity Warrants were converted into Equity Shares

3. The company has realized the 25% upfront money amounting to Rs 1,33,44,999/- against the allotment of 25,79,990 warrants at the price of Rs. 20.69 per warrant and further the company has also realized the balance 75% allotment monies amounting to Rs. 1,30,34,654/-, from the bank account of the respective allottees on against allotment of the equity shares on conversion of the 8,39,997 warrants from the applicants of the aforesaid shares and there is no circulation of funds or mere passing of book entries in this regard.

4. The Company has unutilized money lying in the Escrow account as on 30th June 2021 of which FD is created in the name of the Company in Bank of Baroda for utilizing amount as and when required.



Rakesh Parekh

Chief Financial Officer





